Trading Signals: FOLD Stock Price Prediction and Forecast (Thu. May. 31, 2007 - Fri. Dec. 22, 2023)(Amicus Therapeutics Inc)
| FOLD latest price $10.5100 (-0.94%) ($10.5100 - $10.5100) on Wed. Oct. 26, 2022. | |
| | Trend Analysis and Forecast | | | Average Daily Percentage Swing | 3.35% (three month average) | RSI | 45 | Latest Price | $10.5100(-0.94%) | Stocks Behave Similarly | Similar Stock List | Daily Trend | FOLD declines -0.5% a day on average for past five trading days. | Weekly Trend | FOLD advances 0.7% a week on average for past two weeks. | Market Behavior | Rotation from growth to value for large cap. Normal for small cap. | Correlated ETFs | Broad market will support FOLD advance at 0% a week (0% probability) IBB(55%) IWO(45%) IWM(44%) IWC(43%) IWN(43%) | Factors Impacting FOLD price | FOLD will decline at least -1.675% in a week (0% probabilities). VIXM(-14%) VXX(-12%) UUP(-8%) UNG(-3%) XLU(-2%) | | | | | Relative Volatility | (options are extremely cheap) | | | Market Trend Strength | -1.675% (StdDev 3.35%) | Hourly BBV | -1.9 () | Intraday Trend | 0% | | | |
|
Resistance Level | $10.73 | 5 Day Moving Average | $10.76(-2.32%) | 10 Day Moving Average | $10.83(-2.95%) | 20 Day Moving Average | $10.73(-2.05%) | To recent high | -17.8% | To recent low | 6.9% | Market Cap | $2.714b | | | | Amicus Therapeutics, Inc. is a biotechnology company focused on discovering, developing, and delivering medicines for people living with rare metabolic diseases. The company is committed to advancing and expanding a pipeline of medicines for rare metabolic diseases, including a rare disease gene therapy portfolio. Amicus Therapeutics has a portfolio of product opportunities including the first and only approved oral precision medicine for people living with Fabry disease who have amenable genetic variants; a novel, clinical-stage, treatment paradigm for Pompe disease; and a rare disease gene therapy portfolio. The company was founded on February 4, 2002 and is headquartered in Cranbury, NJ. |